Intrexon | XON


Peers Price Chg Day Year Date
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Arrowhead Research 29.08 1.08 3.86% 30.87% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Bristol-Myers Squibb 47.26 0.12 0.25% -2.58% Sep/08
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ligand Pharmaceuticals 166.75 -0.99 -0.59% 64.87% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
MannKind 5.54 0.20 3.75% -6.58% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Thermo Fisher Scientific 492.60 3.11 0.64% -19.59% Sep/05
Veracyte 32.43 0.91 2.89% 13.51% Sep/05
Xencor 8.55 0.18 2.15% -47.16% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05

Indexes Price Day Year Date
US2000 2391 11.44 0.48% 14.33% Sep/05

Intrexon traded at $1.41 this Tuesday April 9th. Looking back, over the last four weeks, Intrexon lost 9.32 percent. Over the last 12 months, its price rose by 36.89 percent. Looking ahead, we forecast Intrexon to be priced at 1.40 by the end of this quarter and at 1.36 in one year, according to Trading Economics global macro models projections and analysts expectations.

Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. The Company is offering a class of microbe-based biopharmaceuticals that enable the expression and local delivery of disease-modifying therapeutics. Precigen is using precision technology to target intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The Company also focused on studying life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications. The Company’s subsidiaries include PGEN Therapeutics, Inc., Precigen ActoBio, Inc., Exemplar Genetics, LLC and Trans Ova Genetics, L.C.